These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31511436)

  • 1. Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study.
    Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Matsumoto T; Origasa H; Okumura K;
    Circ J; 2019 Sep; 83(10):2017-2024. PubMed ID: 31511436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2823-2833. PubMed ID: 31701593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events.
    Nakamura K; Naito S; Sasaki T; Take Y; Minami K; Kitagawa Y; Motoda H; Inoue M; Otsuka Y; Niijima K; Yamashita E; Sugai Y; Kumagai K; Koyama K; Funabashi N; Oshima S
    Europace; 2019 Feb; 21(2):259-267. PubMed ID: 29982562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use　- A Subanalysis of KYU-RABLE.
    Shinohara T; Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Takita A; Origasa H; Okumura K;
    Circ J; 2022 Jan; 86(2):280-286. PubMed ID: 34275977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures.
    Kottmaier M; Bourier F; Pausch H; Reents T; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Ammar-Busch S; Kaess B; Dillier R; Grebmer C; Kolb C; Hessling G; Deisenhofer I
    Am J Cardiol; 2018 Feb; 121(4):445-449. PubMed ID: 29289359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU-RABLE.
    Shinohara T; Takahashi N; Mukai Y; Kimura T; Yamaguchi K; Takita A; Origasa H; Okumura K;
    J Arrhythm; 2021 Feb; 37(1):70-78. PubMed ID: 33664888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
    Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
    Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
    Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
    Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
    Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Abozguia K; Grimaldi M; Rauer H; Reimitz PE; Smolnik R; Mönninghoff C; Kautzner J
    Eur Heart J; 2019 Sep; 40(36):3013-3021. PubMed ID: 30976787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.